Level Zero Health
Biosensor measurement layer for endocrine biomarkers: disposable DNA-aptamer patch plus handheld reader and data layer that converts interstitial fluid into hormone time-series for clinicians, IVF/TRT practices and clinical researchers. · United Kingdom
London-based medtech building a DNA-aptamer skin patch that measures hormones from interstitial fluid in minutes, with no blood draw and no lab.
Level Zero Health is developing a lab-free hormone measurement platform. Its first product is a single-use patch applied to the skin for 10-15 minutes, read by a compact handheld unit and then discarded; each patch measures one analyte from interstitial fluid. The analytes named by the company are estradiol, progesterone, LH, cortisol and testosterone. A longer-horizon product is a minimally invasive arm-worn patch with microneedles intended to deliver continuous, real-time readings, tentatively targeted for 2028. The commercial model is B2B - technology sold into healthcare provider networks, starting with IVF monitoring and testosterone replacement therapy - plus research partnerships and, eventually, a hormone-health dataset.
Research mapping
Healthspan / Measure (AI) / Biosensor measurement layer for endocrine biomarkers: disposable DNA-aptamer patch plus handheld reader and data layer that converts interstitial fluid into hormone time-series for clinicians, IVF/TRT practices and clinical researchers.
Evidence boundary
Original analysis and independent corroboration remain under development. Commercial scale and durable technical advantage remain under review.
What makes it defensible
Hormone measurement is bottlenecked by venipuncture: every data point needs a clinic, a phlebotomist and a laboratory, which caps sampling frequency and makes hormone dynamics effectively invisible outside a lab. Level Zero claims to remove that dependency by measuring the hormone itself - not a proxy - directly in interstitial fluid with DNA-aptamer biosensors, in minutes, anywhere.
Position in the stack: Sits upstream of clinical decision-making as the sensing/measurement layer: it supplies the disposable sensor, the reader and the resulting data to IVF clinics, TRT/endocrine practices and clinical research organisations, aiming to displace send-out lab immunoassays for frequent-sampling use cases rather than sell direct to consumers.
Who buys it
Founding team
Ula (Ulviyya) Rustamova — Co-founder & CEO — Began coding at 15; built a wearable posture-correction device at 16; software engineering degree; 3+ years at Palantir as Enterprise Tech Lead; Entrepreneur First alum. Named Executive Officer/Director on SEC Form D and director of the UK entity.
Irene (Yiran) Jia — Co-founder & CTO — Professional ballet dancer before injury; double Master's in Innovation Design Engineering (Imperial College London) focused on electrochemical sensors; developed medical devices at Philips; met Rustamova at Entrepreneur First.
SourceFinancing detail
- Last round
- $6.9M Pre-seed (Feb 2025)
Investors: Redalpine (lead), HAX (SOSV), Entrepreneur First, Unruly Capital, Exceptional Ventures, Samos Investments, Anorak Ventures, Springbank Collective, DTX, Black Jays Ventures, Transpose Platform, Angels: Aaron Styer, Joshua Klein, Charlie Bryant
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
Evidence & media
-
Level Zero Health banks $6.9M to prove wearable medtech can take the strain out of hormone testing
What this source supports: Oversubscribed $6.9M pre-seed led by Redalpine with HAX (SOSV) and Entrepreneur First; dual-track strategy (single-use intermittent patch for prescription use, continuous wearable targeted 2028); B2B sale into provider networks; FDA and CE ambitions.
What it does not establish: No valuation, no revenue, no customer names, no clinical data; the 98% figure is not an accuracy result here.
Source -
For the first time, we've shown that clinical-grade hormone measurement without a blood draw is possible
What this source supports: Company-announced first demonstration of clinical-grade, lab-free hormone measurement from interstitial fluid via a single-use skin patch covering E2, P4, LH, cortisol and testosterone; opens partner intake; states it is not a commercial launch.
What it does not establish: No n, no study design, no comparator statistics, no peer-reviewed paper, no verified final hardware - a claim, not evidence.
Source -
Why Continuous Hormone Monitoring Could Transform Women's Health Monitoring
What this source supports: Places Level Zero among the eight SPRIND Stage 1 teams, described as a 'skin-worn electrochemical patch'; contextualises the EUR 40M challenge and the $325.7M (2025) continuous-hormone-monitoring market.
What it does not establish: Single-sentence treatment of Level Zero; no diligence on its data and no independent verification of its claims.
Source
Timeline
-
Customer
~$3M of letters of intent from major IVF clinics reported
Source -
Product
Hiring to industrialise assay manufacturing (lateral flow) in London
Source -
partnership
ESHRE London reception with Genie Fertility and U-Ploid Biotechnologies
Source -
Financing
Selected for SPRIND Continuous Hormone Monitoring Challenge Stage 1 (up to EUR 1.5M non-dilutive)
Source -
Governance
Registered as a UK data controller (ICO)
Source -
Product
Claims first clinical-grade hormone measurement without a blood draw; opens partner call
Source -
Media
Selected as Top 5 Innovation Finalist at ASRM Innovate 2025
Source -
Financing
$6.9M pre-seed announced, led by Redalpine
Source -
Financing
First sale of pre-seed securities
Source -
Product
Feasibility milestone and TechCrunch Disrupt Startup Battlefield pitch
Source -
Governance
UK entity incorporated in London
Source